Intravenous cyclophosphamide therapy in children with calcineurin inhibitor-resistant steroid-resistant nephrotic syndrome in a resource-limited setting.

Paraselli SaitejaBobbity DeepthiSudarsan KrishnasamyMadhileti SravaniSriram Krishnamurthy

Published in: Pediatric nephrology (Berlin, Germany) (2023)

It is prudent to try intravenous cyclophosphamide in CNI-resistant SRNS in LMIC, given the reasonable cost and good efficacy rates (58.6%). A higher resolution version of the Graphical abstract is available as Supplementary information.

Keyphrases

high dose
low dose
young adults
stem cells
single molecule
health information
social media
psychometric properties
smoking cessation
cell therapy